🚨Elon Musk Says He Favors Lily’s Mountaineer Over Novo’s Ozempic

On Wednesday, Elon Musk’s X post highlighted the CEO’s new preference for the Eli Lilly (NYSE: LLY) weight loss therapy moundsaro over Novo Nordisk’s (NVO) rival product Ozempic. (TSLA) Novo Nordisk’s rival product.

Mounjaro and Ozempic, commonly known as Tirzepatide and Semaglutide, are among a new family of diabetes drugs called GLP-1, which are sold as weight loss Zebound and Wegovy, respectively.

“Like a cocaine bear, but Santa and the Olympics!” Musk dressed as Santa Claus in a post titled “Olympics Santa.”

Musk, who is also the head of space exploration company SpaceX, responded to a question about the specific product he uses, saying, “It’s strictly Mounjaro, but it doesn’t mean the same thing.”

“I think texting will have fewer side effects and be more effective,” he explained. Musk, who will be the next co-chair of the government’s efficiency department established by President-elect Donald Trump in 2022, has credited Wegovy with losing weight.

Given his solid support for GLP-1, Musk appears to be at odds with Trump’s nominee for health secretary, Robert F. Kennedy Jr., who has long advocated for dietary control over drugs to fight the obesity epidemic in the United States.

$NVO $LLY